/
We are a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our company was founded on the belief that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible and unencumbered by the safety concerns often associated with…
Negative free cash flow of -$90M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
-$100M
▲ +4.3% YoY
Op. Margin
—
ROIC
-22.97%
▲ +1.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$88M
▲ +13.6% YoY
Op. Cash Flow (TTM)
-$87M
▲ +11.0% YoY
Net Debt
-$155M
Net Cash Position
Cash & Equiv.
$230M
Continue Research